Concepedia

Abdelghani Achab

AA

11

Publications

308

Citations

11

H-Index

2011

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Quantitative BioSciences

WuXi AppTec (China)

Abdelghani Achab is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in drug discovery, medicinal chemistry, and medicine.

Top concepts

Publications per year

2011–2022

11

Publications

11

Structural characterization of nonactive site, TrkA-selective kinase inhibitors

Hua-Poo Su, Keith Rickert, Christine Burlein et al. · Proceedings of the National Academy of Sciences · 2016 · 48 citations · Full text

, , +15

Discovery of Diaminopyrimidine Carboxamide HPK1 Inhibitors as Preclinical Immunotherapy Tool Compounds

Brandon Vara, Samuel M. Levi, Abdelghani Achab et al. · ACS Medicinal Chemistry Letters · 2021 · 47 citations · Full text

Discovery of Amino-cyclobutarene-derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors for Cancer Immunotherapy

Hongjun Zhang, K. Liu, Qinglin Pu et al. · ACS Medicinal Chemistry Letters · 2019 · 44 citations · Full text

Discovery and Hit-to-Lead Optimization of Non-ATP Competitive MK2 (MAPKAPK2) Inhibitors

Xiaohua Huang, Gerald W. Shipps, Cliff C. Cheng et al. · ACS Medicinal Chemistry Letters · 2011 · 33 citations · Full text

, , +16

Discovery and Optimization of Rationally Designed Bicyclic Inhibitors of Human Arginase to Enhance Cancer Immunotherapy

Matthew J. Mitcheltree, Derun Li, Abdelghani Achab et al. · ACS Medicinal Chemistry Letters · 2020 · 30 citations · Full text

Rows per page

1–5 of 11